Related Experiment Video
Updated: Jul 9, 2026
10:02
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Serum beta-glucuronidase levels in children with leprosy
Devki Nandan1, K Venkatesan, Kiran Katoch
1RML Hospital, New Delhi 110 002, India.
Leprosy Review
|November 27, 2007
Summary
Serum beta-glucuronidase levels are elevated in children with leprosy, particularly in lepromatous forms. Treatment with multidrug therapy significantly reduces these enzyme levels, indicating its potential as a marker for disease activity.
Area of Science:
- Biochemistry
- Immunology
- Pediatrics
Background:
- Leprosy is a chronic infectious disease affecting skin and nerves.
- Lysosomal enzymes, such as beta-glucuronidase, play roles in cellular processes.
- Biochemical markers are needed to assess leprosy activity and treatment response.
Purpose of the Study:
- To evaluate the diagnostic and prognostic utility of serum beta-glucuronidase levels in children with leprosy.
- To assess the impact of multidrug therapy on serum beta-glucuronidase levels in pediatric leprosy patients.
Main Methods:
- Serum beta-glucuronidase levels were measured in children under 15 years old.
- Patients included those with leprosy (BB/BL types) and controls (healthy, other skin diseases).
- Enzyme levels were assessed before and after WHO-recommended multidrug therapy.
Main Results:
- Serum beta-glucuronidase levels were significantly higher in leprosy patients (BB/BL) compared to controls.
- A significant decrease in serum beta-glucuronidase was observed after multidrug treatment in BB and BL cases.
- Elevated levels correlated with disease activity and extent of pathogenesis.
Conclusions:
- Serum beta-glucuronidase is a potential biomarker for assessing leprosy activity in children.
- Monitoring serum beta-glucuronidase may aid in evaluating treatment efficacy.
- This enzyme offers insights into the pathogenesis of pediatric leprosy.
